Measurement of CSF alpha-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease

Previous studies have indicated the potential of cerebrospinal fluid (CSF) alpha-synuclein (alpha-syn) to be an additional biomarker for improving differential diagnosis of Alzheimer's disease (AD). We evaluated alpha-syn diagnostic performance across a well-characterized patient cohort with lo...

Descripción completa

Detalles Bibliográficos
Autores: Garcia-Ayllon, Maria-Salud, MONGE, J., Monge-Garcia, Victoria, Navarrete, Francisco, Cortes-Gomez, Maria-Angeles, SANCHEZ, J., Manzanares, Jorge, GASPARINI, R., LEIVA, C., SAEZ, J.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p3536
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/3536
Access Level:acceso abierto
Palabra clave:Alzheimer
biomarker
diagnosis
Lewy body disease
mild cognitive impairment
alpha-synuclein
Descripción
Sumario:Previous studies have indicated the potential of cerebrospinal fluid (CSF) alpha-synuclein (alpha-syn) to be an additional biomarker for improving differential diagnosis of Alzheimer's disease (AD). We evaluated alpha-syn diagnostic performance across a well-characterized patient cohort with long-term follow-up. For this purpose, CSF alpha-syn levels were determined in 25 subjects diagnosed with stable mild cognitive impairment (stable MCI; n = 25), 27 MCI cases due to AD (MCI-AD; n = 32), 24 MCI cases due to Lewy body disease (MCI-LBD; n = 24) and control subjects (Ctrl; n = 18). CSF alpha-syn levels discriminate between the four groups. There were higher alpha-syn levels in MCI-AD patients and lower levels in MCI-LBD patients. The combination of alpha-syn and P-tau resulted in a specificity of 99% and a sensitivity of 97% for MCI-AD. MCI-AD patients with early psychotic symptoms (n = 9) displayed a trend towards a decrease in P-tau and alpha-syn compared to the MCI-AD patients without psychotic symptoms (n = 23). We conclude that adding CSF alpha-syn to central core AD biomarkers improves an early differential diagnosis of MCI-AD from other forms of MCI.

Similares en LA Referencia